// App-Quantinova.ai

1052 : TET2 and DNMT3A Mutations Exert Divergent Effects on DNA Repair and Sensitivity of Leukemia Cells to PARP Inhibitors

Researchers

Presenter

  • Silvia Maifrede

Principal Investigators

  • Margaret Nieborowska-Skorska

  • Konstantin Golovine

  • Katherine Sullivan-Reed

  • Wangisa M.B. Dunuwille

  • Joseph Nacson

  • Michael Hulse

  • Lisa Beatrice Caruso

  • Zachary Gazze

  • Zhaorui Lian

  • Antonella Padella

  • Kumaraswamy Chitrala

  • Boris Bartholdy

  • Ksenia Matlawska-Wasowska

  • Daniela Di Marcantonio

  • Giorgia Simonetti

  • Georg Greiner

  • Stephen M. Sykes

  • Peter Valent

  • Elisabeth M. Paietta

  • Hugo F Fernandez

  • Martin S. Tallman

  • Mark Litzow

  • Mark D. Minden

  • Jian Huang

  • Giovanni Martinelli

  • George S. Vassiliou

  • Italo Tempera

  • Katarzyna Piwocka

  • Neil Johnson

  • Grant Challen

  • Tomasz Skorski

Medical Centers

  • Temple University School of Medicine, Philadelphia, PA

  • Washington University School of Medicine, St. Louis, MO

  • Fox Chase Cancer Center, Philadelphia, PA

  • University of Bologna, Rome, Italy

  • Albert Einstein College of Medicine, Great Neck, NY

  • University of New Mexico, Albuquerque, NM

  • Medical University of Vienna, Vienna, Austria

  • Department for Medicine I/Clinical Division of Oncology, Medical University of Vienna, Vienna, Austria

  • Albert Einstein College of Medicine, Great Neck, NY

  • Moffitt Malignant Hematology & Cellular Therapy at Memorial Healthcare System, Pembroke Pines

  • Memorial Sloan Kettering Cancer Center, Port Washington, NY

  • Division of Medical Oncology, Mayo Clinic, Rochester, MN

  • Medical Oncology and Hematology, Princess Margaret Cancer Centre, University Health Network, Toronto, ON, Canada

  • Wellcome Trust Sanger Institute, Cambridge, United Kingdom

  • Nencki Institute of Experimental Biology PAS, Warsaw, Poland

  • Washington University School of Medicine, St. Louis, MO

Locations

  • United States

  • Italy

  • Austria

  • Canada

  • United Kingdom

  • Poland

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Hematological malignancies

  • Hereditary susceptibility to Wilms tumor 5

  • Solid malignancies

Biomarkers

  • Breast cancer type 1 susceptibility protein

  • Breast cancer type 2 susceptibility protein

  • Poly(ADP-Ribose) Polymerase 1

  • WT1 Transcription Factor

  • DNA methylation

Drug/Treatment

  • L-Tyrosine

Outcome

  • N/A

Study Design

  • N/A

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved